

Dimitrios Tzachanis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9343331/publications.pdf>

Version: 2024-02-01

68
papers

1,699
citations

430874

18
h-index

289244

40
g-index

69
all docs

69
docs citations

69
times ranked

2527
citing authors

#	ARTICLE	IF	CITATIONS
1	Recent Advances in CAR T-Cell Therapy for Patients with Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022, 14, 1715.	3.7	9
2	Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. <i>Blood</i> , 2022, 140, 2248-2260.	1.4	20
3	Chronic oral graft-versus-host disease: induction and maintenance therapy with photobiomodulation therapy. <i>Supportive Care in Cancer</i> , 2021, 29, 1387-1394.	2.2	9
4	In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden. <i>Cytotherapy</i> , 2021, 23, 320-328.	0.7	8
5	Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021, 194, 690-700.	2.5	88
6	KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. <i>Lancet</i> , The, 2021, 398, 491-502.	13.7	315
7	Assessing CAR T-cell therapy response using genome-wide sequencing of cell-free DNA in patients with B-cell lymphomas. <i>Transplantation and Cellular Therapy</i> , 2021, 28, 30.e1-30.e1.	1.2	11
8	Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6). <i>Blood</i> , 2021, 138, 2832-2832.	1.4	4
9	A Randomized Phase II Trial Comparing a Calcineurin Inhibitor-Free Graft-Versus-Host Disease Prophylaxis Regimen with Post-Transplantation Cyclophosphamide and Abatacept to Standard of Care. <i>Blood</i> , 2021, 138, 1816-1816.	1.4	2
10	Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7). <i>Blood</i> , 2021, 138, 430-430.	1.4	9
11	Intensive Induction Therapy Compared With CHOP for Hepatosplenic T-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 431-437.e2.	0.4	3
12	Local immune cell infiltration in cutaneous acute graft versus host disease. <i>International Journal of Women's Dermatology</i> , 2020, 6, 311-317.	2.0	0
13	Extramedullary early T-cell precursor acute lymphoblastic lymphoma presenting as blast crisis of CML. <i>Blood</i> , 2020, 136, 1112-1112.	1.4	1
14	Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic. <i>Lancet Oncology</i> , The, 2020, 21, 759-760.	10.7	34
15	Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 599-634.	4.9	33
16	A Pilot Study Using EMR (Electronic Medical Record) and BMT (Bone Marrow Transplant) Registry Data to Evaluate Health Service Utilization in BMT Patients with Depression and Comorbid Conditions at an Academic Cancer Center. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S274.	2.0	0
17	Depression and Infection Rates in Hematopoietic Stem Cell Transplant Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S375-S376.	2.0	0
18	Reduced-Intensity Conditioning Regimens, Prior Chronic Lymphocytic Leukemia, and Graft-Versus-Host Disease Are Associated with Higher Rates of Skin Cancer after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Investigative Dermatology</i> , 2019, 139, 591-599.	0.7	17

#	ARTICLE	IF	CITATIONS
19	Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504. <i>Blood</i> , 2019, 134, 3880-3880.	1.4	12
20	Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL. <i>Blood</i> , 2019, 134, 1755-1755.	1.4	1
21	Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. <i>Blood</i> , 2018, 131, 2836-2845.	1.4	30
22	Tachyphylaxis to the Sedative Action of Mirtazapine. <i>American Journal of Case Reports</i> , 2018, 19, 410-412.	0.8	2
23	Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. <i>Current Neuropharmacology</i> , 2018, 16, 1210-1223.	2.9	98
24	A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401. <i>Blood</i> , 2018, 132, 4018-4018.	1.4	1
25	Protmune, a Next-Generation Graft for GvHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: 1-Year Safety and Efficacy Phase 1 Data. <i>Blood</i> , 2018, 132, 2167-2167.	1.4	0
26	Exposure to the drug company marketing in Greece: Interactions and attitudes in a non-regulated environment for medical students. <i>Annals of Medicine and Surgery</i> , 2017, 19, 23-28.	1.1	6
27	L-carnitine for pegylated-l-asparaginase induced hepatotoxicity.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21626-e21626.	1.6	3
28	A Case of Subacute Encephalopathy Developing After Treatment With Clofarabine and Methotrexate That Resolved With Corticosteroids. <i>American Journal of Therapeutics</i> , 2016, 23, e937-e940.	0.9	3
29	Complex management of resistant oral herpes simplex virus infection following hematopoietic stem cell transplantation: potential role of topical cidofovir. <i>Supportive Care in Cancer</i> , 2016, 24, 3603-3606.	2.2	11
30	CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. <i>Blood</i> , 2016, 127, 3360-3368.	1.4	89
31	Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium. <i>Leukemia and Lymphoma</i> , 2016, 57, 1731-1734.	1.3	24
32	Early diagnosis and successful management of oral mucormycosis in a hematopoietic stem cell transplant recipient: case report and literature review. <i>Supportive Care in Cancer</i> , 2016, 24, 3343-3346.	2.2	12
33	Yttrium-90 Ibritumomab Tiuxetan Followed by Rituximab Maintenance as Treatment for Patients with Diffuse Large B-Cell Lymphoma Are Not Candidates for Autologous Stem Cell Transplant. <i>Acta Haematologica</i> , 2015, 133, 347-353.	1.4	7
34	Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion-1 (NCT01677858). <i>Blood</i> , 2015, 126, 373-373.	1.4	4
35	Updated results from CHAMPION-1, a phase I/II study investigating weekly carfilzomib with dexamethasone for patients (Pts) with relapsed or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8527-8527.	1.6	3
36	Primary Cardiac Burkitt Lymphoma Presenting with Abdominal Pain. <i>Case Reports in Hematology</i> , 2014, 2014, 1-4.	0.4	6

#	ARTICLE	IF	CITATIONS
37	Successful Treatment of Refractory Guillain-Barré Syndrome with Alemtuzumab in a Patient with Chronic Lymphocytic Leukemia. <i>Acta Haematologica</i> , 2014, 132, 240-243.	1.4	15
38	A 78-Year-Old Man with Acute Myeloid Leukemia (AML) and Acute Renal Failure. <i>American Journal of Case Reports</i> , 2014, 15, 364-367.	0.8	5
39	Pregabalin's abuse potential: a mini review focusing on the pharmacological profile. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 709-716.	0.6	43
40	Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients. <i>Clinical Cancer Research</i> , 2013, 19, 3640-3648.	7.0	199
41	Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 578-578.	1.4	3
42	Targeting Leukemia Initiating Cells by MUC1-C Subunit Inhibition. <i>Blood</i> , 2012, 120, 3583-3583.	1.4	0
43	Transduction of Malignant Plasma Cells with Three Costimulatory Molecules (TRICOM) Elicits Myeloma-Specific Immune Response in Vitro – a Promising Strategy for Immunotherapy. <i>Blood</i> , 2012, 120, 1908-1908.	1.4	35
44	Clinical Trial Evaluating DC/AML Fusion Cell Vaccination Alone and in Conjunction with PD-1 Blockade in AML Patients Who Achieve a Chemotherapy-Induced Remission. <i>Blood</i> , 2011, 118, 948-948.	1.4	3
45	MUC1 Inhibition Reverses the Poor Immunogenicity of Leukemia Stem Cells Rendering Them Susceptible to Immunotherapy. <i>Blood</i> , 2011, 118, 1883-1883.	1.4	0
46	Addition of Clofarabine to TLI/ATG Conditioning: Impact on Immune Reconstitution and Clinical Outcomes. <i>Blood</i> , 2011, 118, 4066-4066.	1.4	0
47	Cancer vaccines in hematologic malignancies: advances, challenges and therapeutic potential. <i>Expert Review of Vaccines</i> , 2010, 9, 451-454.	4.4	1
48	Targeting Acute Myeloid Leukemia Stem Cells by MUC1-C Subunit Inhibition. <i>Blood</i> , 2010, 116, 848-848.	1.4	1
49	90Y-Ibritumomab Tiuxetan Followed by Rituximab Is a Safe Treatment Option for Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2010, 116, 2866-2866.	1.4	1
50	Tob, a member of the APRO family, regulates immunological quiescence and tumor suppression. <i>Cell Cycle</i> , 2009, 8, 1019-1025.	2.6	31
51	Dendritic Cell Tumor Fusion Vaccination in Conjunction with Autologous Transplantation for Multiple Myeloma. <i>Blood</i> , 2009, 114, 783-783.	1.4	2
52	A Comparative Analysis of Immune Reconstitution Following Reduced Intensity Conditioning with CAMPATH-1H and Total Lymphoid Irradiation/Anti-Thymocyte Globulin Prior to Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2009, 114, 1148-1148.	1.4	0
53	Neuroprotection by lamotrigine in a rat model of neonatal hypoxic-ischaemic encephalopathy. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 321-9.	2.1	23
54	Fusion Cell Vaccination in Conjunction with Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and Is Associated with Responses in Patients with Multiple Myeloma. <i>Blood</i> , 2008, 112, 826-826.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Immunomodulatory Effects of Vitamin D: Implications for the Prevention and Treatment of Graft Versus Host Disease. <i>Blood</i> , 2008, 112, 1251-1251.	1.4	0
56	Development of CMV-SPECIFIC Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of NAIVE CD8+ T Cells. <i>Blood</i> , 2008, 112, 1167-1167.	1.4	0
57	Weekly docetaxel regimens and radiation pneumonitis. <i>The Journal of Supportive Oncology</i> , 2008, 6, 265-6.	2.3	0
58	Twisted gastrulation (Tsg) is regulated by Tob and enhances TGF- β signaling in activated T lymphocytes. <i>Blood</i> , 2007, 109, 2944-2952.	1.4	14
59	Rap1-GTP Is a Negative Regulator of Th Cell Function and Promotes the Generation of CD4+CD103+ Regulatory T Cells In Vivo. <i>Journal of Immunology</i> , 2005, 175, 3133-3139.	0.8	33
60	Twisted Gastrulation (Tsg), an Evolutionarily Conserved, Secreted, Morphogenetic Protein Enhances TGF- β Signaling in T Lymphocytes.. <i>Blood</i> , 2005, 106, 341-341.	1.4	2
61	Intrinsic and Extrinsic Regulation of T Lymphocyte Quiescence. <i>Leukemia and Lymphoma</i> , 2004, 45, 1959-1967.	1.3	41
62	Rap1-GTP Promotes the Generation of Regulatory T Cells in Vivo.. <i>Blood</i> , 2004, 104, 110-110.	1.4	2
63	The E3 Ubiquitin Ligase TRIM36, a Transcriptional Target of Tob, Is Expressed in Anergic T Cells and Mediates Unresponsiveness through Proteolysis of Signaling Proteins PLC- β 1 and PKC- ζ .. <i>Blood</i> , 2004, 104, 113-113.	1.4	2
64	Differential Localization and Function of ADP-Ribosylation Factor-6 in Anergic Human T Cells: A Potential Marker for Their Identification. <i>Journal of Immunology</i> , 2003, 171, 1691-1696.	0.8	7
65	Induction of Immunologic Tolerance for Allogeneic Hematopoietic Cell Transplantation. <i>Leukemia and Lymphoma</i> , 2002, 43, 1159-1167.	1.3	8
66	Blockade of B7/CD28 in mixed lymphocyte reaction cultures results in the generation of alternatively activated macrophages, which suppress T-cell responses. <i>Blood</i> , 2002, 99, 1465-1473.	1.4	53
67	Helper T cell anergy: from biochemistry to cancer pathophysiology and therapeutics. <i>Journal of Molecular Medicine</i> , 2001, 78, 673-683.	3.9	48
68	Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. <i>Nature Immunology</i> , 2001, 2, 1174-1182.	14.5	250